Discovery of Peptide Inhibitors for GDF15-GFRaL-RET Signaling Complex Offers New Avenues for Disease Treatment

Strategic Insights -

Research conducted by Sophie Watcham and colleagues at BicycleTx Limited in Cambridge, UK, has led to the discovery of peptide inhibitors that can prevent the activity of the GDF15-GFRaL-RET signaling complex, a key player in various disease states, including cancer and wasting disorders like cachexia. The researchers used a structure-guided design and phage display approach to develop bicyclic peptide hits with high affinity for GFRaL, which were then dimerized to mimic the bidentate interaction of homodimeric GDF15. These dimerized protein mimetics inhibited cell signaling in a functional assay and showed improved pharmacokinetic properties compared to their monomeric counterparts.

Key Takeaways:

  • The GDF15-GFRaL-RET signaling complex is involved in a broad range of disease states, including cancer and wasting disorders like cachexia.
  • Peptide inhibitors of the GDF15-GFRaL protein-protein interaction have been discovered using both structure-guided design and phage display approach.
  • Bicyclic peptide hits with high affinity for GFRaL were found through phage display, and these were dimerized to mimic the bidentate interaction of homodimeric GDF15.
  • Dimerized protein mimetics inhibited cell signaling in a functional assay and showed improved pharmacokinetic properties compared to their monomeric counterparts.
  • This research is the first example of a homodimeric bicycle molecule inhibiting receptor complex formation, thereby antagonizing the intracellular signaling response.
  • The study highlights the potential of peptide inhibitors for the treatment of diseases involving the GDF15-GFRaL-RET signaling complex.

Statistics:

  • The GDF15-GFRaL-RET signaling complex involves a broad range of disease states, including cancer, wasting disorders like cachexia, and metabolism control.
  • The peptide inhibitors developed in this study showed picomolar affinities, similar to that of the endogenous GDF15 ligand.
  • The dimerized protein mimetics inhibited cell signaling in a functional assay, demonstrating their potential as therapeutic agents.
  • The research was conducted at BicycleTx Limited in Cambridge, UK, and involved a team of researchers including Sophie Watcham, Anais F. M. Noisier, Jenny Sandmark, Fredrik Edfeldt, and others.

Sources:

  • NewsRx. Findings on Life Science from Sophie Watcham and Colleagues Provide New Insights (Design of Bicyclic Peptide Tandems Mimicking the Homodimeric GDF15 Protein to Inhibit GDF15-GFRaL-RET Complex Cell Signaling). Life Science Weekly. October 21, 2025; p 1622.
  • Journal of Medicinal Chemistry. Design of Bicyclic Peptide Tandems Mimicking the Homodimeric GDF15 Protein to Inhibit GDF15-GFRaL-RET Complex Cell Signaling. 2025.